본문 바로가기
KERD
논문KCI 등재

Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019

Eun Hui Bae|Seong Kwon Ma|Soo Wan Kim|Sang Heon Suh
대한내과학회 (The Korean Association Of Internal Medicine)|2021.03|The Korean Journal of Internal Medicine|제36권 제2호|pp. 247-262|DOI https://doi.org/10.3904/kjim.2020.355

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

COVID-19Cardiovascular diseasesKidney diseasesSevere acute respiratory syndrome coronavirus 2Angiotensin converting enzyme 2
주제분류내과학

초록

In the decades since the discovery of angiotensin-converting enzyme 2 (ACE2), its protective role in terms of antagonizing activation of the classical renin-angiotensin system (RAS) axis has been recognized in clinical and experimental studies on kidney and cardiovascular diseases. The effects of ACE inhibitor/angiotensin type 1 receptor blockers (ACEi/ARBs) on ACE2-angiotensin-(1-7) (Ang- (1-7))-Mas receptor (MasR) axis activation has encouraged the use of such blockers in patients with kidney and cardiovascular diseases, until the emergence of coronavirus disease 2019 (COVID-19). The previously unchallenged functions of the ACE2-Ang-(1-7)-MasR axis and ACEi/ARBs are being re-evaluated in the era of COVID-19; the hypothesis is that ACEi/ARBs may increase the risk of severe acute respiratory syndrome coronavirus 2 infection by upregulating the human ACE2 receptor expression level. In this review, we examine ACE2 molecular structure, function (as an enzyme of the RAS), and distribution. We explore the roles played by ACE2 in kidney, cardiovascular, and pulmonary diseases, highlighting studies that defined the benefits imparted when ACEi/ARBs activated the local ACE2- Ang-(1-7)-MasR axis. Finally, the question of whether ACEi/ARBs therapies should be stopped in COVID-19-infected patients will be reviewed by reference to the available evidence.

Abstract

In the decades since the discovery of angiotensin-converting enzyme 2 (ACE2), its protective role in terms of antagonizing activation of the classical renin-angiotensin system (RAS) axis has been recognized in clinical and experimental studies on kidney and cardiovascular diseases. The effects of ACE inhibitor/angiotensin type 1 receptor blockers (ACEi/ARBs) on ACE2-angiotensin-(1-7) (Ang- (1-7))-Mas receptor (MasR) axis activation has encouraged the use of such blockers in patients with kidney and cardiovascular diseases, until the emergence of coronavirus disease 2019 (COVID-19). The previously unchallenged functions of the ACE2-Ang-(1-7)-MasR axis and ACEi/ARBs are being re-evaluated in the era of COVID-19; the hypothesis is that ACEi/ARBs may increase the risk of severe acute respiratory syndrome coronavirus 2 infection by upregulating the human ACE2 receptor expression level. In this review, we examine ACE2 molecular structure, function (as an enzyme of the RAS), and distribution. We explore the roles played by ACE2 in kidney, cardiovascular, and pulmonary diseases, highlighting studies that defined the benefits imparted when ACEi/ARBs activated the local ACE2- Ang-(1-7)-MasR axis. Finally, the question of whether ACEi/ARBs therapies should be stopped in COVID-19-infected patients will be reviewed by reference to the available evidence.

참고문헌 (138)

  1. Donoghue M, "A novel angiotensin-converting enzyme-related carboxypeptidase(ACE2)converts angiotensin I to angiotensin 1-9", Circ Res, 87, pp.E1~E9 (2000)
  2. Tipnis SR, "A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase", J Biol Chem, 275, pp.33238~33243 (2000)
  3. Higuchi S, "Angiotensin II signal transduction through the AT1receptor: novel insights into mechanisms and pathophysiology", Clin Sci(Lond), 112, pp.417~428 (2007)
  4. Brenner BM, "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", N Engl J Med, 345, pp.861~869 (2001)
  5. Lewis EJ, "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", N Engl J Med, 345, pp.851~860 (2001)
  6. Lewis EJ, "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group", N Engl J Med, 329, pp.1456~1462 (1993)
  7. Kostenis E, "G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor", Circulation, 111, pp.1806~1813 (2005)
  8. Culver S, "Intrarenal angiotensin-converting enzyme : the old and the new", Curr Hypertens Rep, 19, pp.80~ (2017)
  9. Williams VR, "Angiotensin-converting enzyme 2 and renal disease", Curr Opin Nephrol Hypertens, 27, pp.35~41 (2018)
  10. Wysocki J, "Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2 : prevention of angiotensin II-dependent hypertension", Hypertension, 55, pp.90~98 (2010)
  11. Zhong J, "Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2", Hypertension, 57, pp.314~322 (2011)
  12. Callera GE, "Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2", AT2R, Biosci Rep, pp.2016, 36[DOI]
  13. Ferrario CM, "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2", Circulation, 111, pp.2605~2610 (2005)
  14. Ocaranza MP, "Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat", Hypertension, 48, pp.572~578 (2006)
  15. Ishiyama Y, "Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors", Hypertension, 43, pp.970~976 (2004)
  16. Walls AC, "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", Cell, 181, pp.281~292 (2020)
  17. Yan R, "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2", Science, 367, pp.1444~1448 (2020)
  18. Wan Y, "Receptor recognition by the novel coronavirus from Wuhan : an analysis based on decade-long structural studies of SARS coronavirus", J Virol, 94, pp.e00127~20 (2020)
  19. Yang X, "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China : a single-centered, retrospective, observational study", Lancet Respir Med, 8, pp.475~481 (2020)
  20. Diaz JH, "Hypothesis : angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19", J Travel Med, 27, pp.taaa041~ (2020)
  21. Esler M, "Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?", J Hypertens, 38, pp.781~782 (2020)
  22. Rice GI, "Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism", Biochem J, 383(Pt 1), pp.45~51 (2004)
  23. Santos RA, "Angiotensin-(1-7)is an endogenous ligand for the G protein-coupled receptor Mas", Proc Natl Acad Sci U S A, 100, pp.8258~8263 (2003)
  24. Vickers C, "Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase", J Biol Chem, 277, pp.14838~14843 (2002)
  25. Georgiadis D, "Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin : insights from selective inhibitors", Circ Res, 93, pp.148~154 (2003)
  26. Chappell MC, "Metabolism of angiotensin-(1-7)by angiotensin-converting enzyme", Hypertension, 31(1 Pt 2), pp.362~367 (1998)
  27. Deddish PA, "N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme : angiotensin-(1-7)and keto-ACE", Hypertension, 31, pp.912~917 (1998)
  28. Aronson JK, "Drugs and the renin-angiotensin system in covid-19", BMJ, 369, pp.m1313~ (2020)
  29. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
  30. Ruiz-Ortega M, "Angiotensin II : a key factor in the inflammatory and fibrotic response in kidney diseases", Nephrol Dial Transplant, 21, pp.16~20 (2006)
  31. Pinheiro SVB, "Genetic deletion of the angiotensin-(1-7)receptor Mas leads to glomerular hyperfiltration and microalbuminuria", Kidney Int, 75, pp.1184~1193 (2009)
  32. Tikellis C, "Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy", Hypertension, 41, pp.392~397 (2003)
  33. Agata J, "Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme", Hypertens Res, 29, pp.865~874 (2006)
  34. Ferrario CM, "Effects of renin-angiotensin system blockade on renal angiotensin-(1-7)forming enzymes and receptors", Kidney Int, 68, pp.2189~2196 (2005)
  35. Patel VB, "Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE", ADAM-17 : a positive feedback mechanism in the RAS, 2014, pp.66, 167~176
  36. Wu L, "Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury", Circulation, 104, pp.2716~2721 (2001)
  37. Walters PE, "Angiotensin-(1-7)acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats", Hypertension, 45, pp.960~966 (2005)
  38. Bosnyak S, "Differential mechanisms of ang(1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats", Int J Hypertens, 2012, pp.192567~ (2012)
  39. Koulis C, "AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy", Hypertension, 65, pp.1073~1081 (2015)
  40. Matavelli LC, "A nonpeptide angiotensin II type 2 receptor agonist prevents renal inflammation in early diabetes", J Cardiovasc Pharmacol, 65, pp.371~376 (2015)
  41. Dhande I, "Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10 : role in renoprotection in obese rats", Hypertension, 61, pp.1218~1226 (2013)
  42. Kemp BA, "AT2 receptor activation prevents sodium retention and reduces blood pressure in angiotensin II-dependent hypertension", Circ Res, 119, pp.532~543 (2016)
  43. Hamming I, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", J Pathol, 203, pp.631~637 (2004)
  44. Vuille-dit-Bille RN, "Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors", Amino Acids, 47, pp.693~705 (2015)
  45. Paizis G, "Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2", Gut, 54, pp.1790~1796 (2005)
  46. Wong DW, "Loss of angiotensin-converting enzyme-2(Ace2)accelerates diabetic kidney injury", Am J Pathol, 171, pp.438~451 (2007)
  47. Chen L, "The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2", Cardiovasc Res, 116, pp.1097~1100 (2020)
  48. Zou X, "Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection", Front Med, 14, pp.185~192 (2020)
  49. Ziegler CGK, "SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues", Cell, 181, pp.1016~1035 (2020)
  50. Paul M, "Physiology of local renin-angiotensin systems", Physiol Rev, 86, pp.747~803 (2006)
  51. Price DA, "The paradox of the low-renin state in diabetic nephropathy", J Am Soc Nephrol, 10, pp.2382~2391 (1999)
  52. Tikellis C, "ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes", Diabetes, 57, pp.1018~1025 (2008)
  53. Shiota A, "Loss of ACE2accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice", Hypertens Res, 33, pp.298~307 (2010)
  54. Wysocki J, "Regulation of urinary ACE2 in diabetic mice", Am J Physiol Renal Physiol, 305, pp.F600~F611 (2013)
  55. Chodavarapu H, "Rosiglitazone treatment of type 2 diabetic db", db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion, 2013, pp.8, e62833~
  56. Lambert DW, "Tumor necrosis factor-alpha convertase(ADAM17)mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus(SARS-CoV)receptor, angiotensin-converting enzyme-2(ACE2)", J Biol Chem, 280, pp.30113~30119 (2005)
  57. Reddy AB, "Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor(TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells", Endocrinology, 150, pp.63~74 (2009)
  58. Xiao F, "Protein kinase C-δ mediates shedding of angiotensin-converting enzyme 2 from proximal tubular cells", Front Pharmacol, 7, pp.146~ (2016)
  59. Bae EH, "Characterization of the intrarenal renin-angiotensin system in experimental alport syndrome", Am J Pathol, 185, pp.1423~1435 (2015)
  60. Oudit GY, "Human recombinant ACE2 reduces the progression of diabetic nephropathy", Diabetes, 59, pp.529~538 (2010)
  61. Chen LJ, "Angiotensin-converting enzyme 2 ameliorates renal fibrosis by blocking the activation of mTOR", ERK signaling in apolipoprotein E-deficient mice, 2016, pp.79, 49~57
  62. Bae EH, "Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome", Kidney Int, 91, pp.1347~1361 (2017)
  63. Wysocki J, "Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy", Kidney Int, 91, pp.1336~1346 (2017)
  64. Soler MJ, "Localization of ACE2 in the renal vasculature : amplification by angiotensin II type 1 receptor blockade using telmisartan", Am J Physiol Renal Physiol, 296, pp.F398~F405 (2009)
  65. Suh SH, "Olmesartan attenuates kidney fibrosis in a murine model of alport syndrome by suppressing tubular expression of TGFβ", Int J Mol Sci, 20, pp.3843~ (2019)
  66. Goru SK, "Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT2 receptor expression in a rat model of type 1 diabetes", Br J Pharmacol, 174, pp.3118~3130 (2017)
  67. Huskova Z, "Intrarenal alterations of the angiotensin-converting enzyme type 2", angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats, 2016, pp.43, 438~449
  68. Suh SH, "CG200745, a novel HDAC inhibitor, attenuates kidney fibrosis in a murine model of Alport syndrome", Int J Mol Sci, 21, pp.1473~ (2020)
  69. Yuan W, "1, 25-Dihydroxyvitamin D3suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter", J Biol Chem, 282, pp.29821~29830 (2007)
  70. Lin M, "Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease", Mol Biol Rep, 43, pp.397~406 (2016)
  71. Riera M, "Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria", Am J Physiol Renal Physiol, 310, pp.F534~F546 (2016)
  72. de Jong MA, "Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis", Nephrol Dial Transplant, 32, pp.73~80 (2017)
  73. de Borst MH, "Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease", J Am Soc Nephrol, 22, pp.1603~1609 (2011)
  74. Humalda JK, "Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade", Am J Kidney Dis, 65, pp.259~266 (2015)
  75. Zoccali C, "Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition", J Am Soc Nephrol, 22, pp.1923~1930 (2011)
  76. Mizuiri S, "Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls", Am J Kidney Dis, 51, pp.613~623 (2008)
  77. Reich HN, "Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease", Kidney Int, 74, pp.1610~1616 (2008)
  78. Wang M, "Nodular glomerulosclerosis and renin angiotensin system in Chinese patients with type 2 diabetes", Mol Cell Endocrinol, 427, pp.92~100 (2016)
  79. Mizuiri S, "Urinary angiotensin-converting enzyme 2 in patients with CKD", Nephrology(Carlton), 16, pp.567~572 (2011)
  80. Rigatto K, "Diminazene aceturate improves autonomic modulation in pulmonary hypertension", Eur J Pharmacol, 713, pp.89~93 (2013)
  81. Burns KD, "The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1diabetes", Am J Physiol Renal Physiol, 312, pp.F335~F342 (2017)
  82. Basu R, "Loss of TIMP3 selectively exacerbates diabetic nephropathy", Am J Physiol Renal Physiol, 303, pp.F1341~F1352 (2012)
  83. Patel VB, "Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling", Hypertension, 64, pp.157~164 (2014)
  84. Patel VB, "ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity", Diabetes, 65, pp.85~95 (2016)
  85. Sampaio WO, "Angiotensin-(1-7)through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways", Hypertension, 49, pp.185~192 (2007)
  86. Santos RA, "Impairment of in vitro and in vivo heart function in angiotensin-(1-7)receptor MAS knockout mice", Hypertension, 47, pp.996~1002 (2006)
  87. Sampaio WO, "Angiotensin-(1-7)counterregulates angiotensin II signaling in human endothelial cells", Hypertension, 50, pp.1093~1098 (2007)
  88. Iwata M, "Angiotensin-(1-7)binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects", Am J Physiol Heart Circ Physiol, 289, pp.H2356~H2363 (2005)
  89. Burrell LM, "Myocardial infarction increases ACE2 expression in rat and humans", Eur Heart J, 26, pp.369~375 (2005)
  90. Xie X, "Age-and gender-related difference of ACE2 expression in rat lung", Life Sci, 78, pp.2166~2171 (2006)
  91. Kassiri Z, "Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction", Circ Heart Fail, 2, pp.446~455 (2009)
  92. Qi YF, "Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia", J Mol Med(Berl), 94, pp.37~49 (2016)
  93. Wang Y, "Circulating rather than cardiac angiotensin-(1-7)stimulates cardioprotection after myocardial infarction", Circ Heart Fail, 3, pp.286~293 (2010)
  94. Wang W, "Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease", J Mol Med(Berl), 92, pp.847~858 (2014)
  95. Patel VB, "Epicardial adipose tissue as a metabolic transducer : role in heart failure and coronary artery disease", Heart Fail Rev, 22, pp.889~902 (2017)
  96. Packer M, "Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium", J Am Coll Cardiol, 71, pp.2360~2372 (2018)
  97. Patel VB, "ACE2", Ang 1-7 axis : a critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity, 2016, pp.5, 306~311
  98. Crackower MA, "Angiotensin-converting enzyme 2 is an essential regulator of heart function", Nature, 417, pp.822~828 (2002)
  99. Diez-Freire C, "ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR", Physiol Genomics, 27, pp.12~19 (2006)
  100. Rentzsch B, "Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function", Hypertension, 52, pp.967~973 (2008)
  101. Verma A, "ACE2 and Ang-(1-7)confer protection against development of diabetic retinopathy", Mol Ther, 20, pp.28~36 (2012)
  102. Dominguez JM 2nd, "Adeno-associated virus overexpression of angiotensin-converting enzyme-2 reverses diabetic retinopathy in type 1 diabetes in mice", Am J Pathol, 186, pp.1688~1700 (2016)
  103. Jarajapu YP, "Activation of the ACE2", angiotensin-(1-7), Diabetes, pp.2013, 62[DOI]
  104. Igase M, "Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7)expression in the aorta of spontaneously hypertensive rats", Am J Physiol Heart Circ Physiol, 289, pp.H1013~H1019 (2005)
  105. Jessup JA, "Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats", Am J Physiol Heart Circ Physiol, 291, pp.H2166~H2172 (2006)
  106. Jin HY, "ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production", PLoS One, 7, pp.e38502~ (2012)
  107. Yilin Z, "Role of angiotensin-converting enzyme(ACE)and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome", Burns, 41, pp.1468~1477 (2015)
  108. Imai Y, "Angiotensin-converting enzyme 2 protects from severe acute lung failure", Nature, 436, pp.112~116 (2005)
  109. Kuba K, "A crucial role of angiotensin converting enzyme 2(ACE2)in SARS coronavirus-induced lung injury", Nat Med, 11, pp.875~879 (2005)
  110. Rey-Parra GJ, "Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury", J Mol Med(Berl), 90, pp.637~647 (2012)
  111. Hemnes AR, "A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension", Eur Respir J, 51, pp.1702638~ (2018)
  112. Fang Y, "Angiotensin-converting enzyme 2attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-κB and Nrf2pathways", QJM, 112, pp.914~924 (2019)
  113. Yuan YM, "Activation of renin-angiotensin-aldosterone system(RAAS)in the lung of smoking-induced pulmonary arterial hypertension(PAH)rats", J Renin Angiotensin Aldosterone Syst, 16, pp.249~253 (2015)
  114. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
  115. Li G, "Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19", J Autoimmun, 112, pp.102463~ (2020)
  116. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
  117. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
  118. McMichael TM, "Epidemiology of COVID-19 in a long-term care facility in King County, Washington", N Engl J Med, 382, pp.2005~2011 (2020)
  119. Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
  120. Li G, "Antihypertensive treatment with ACEI", ARB of patients with COVID-19 complicated by hypertension, 2020, pp.43, 588~590
  121. Marin GH, "Facts and reflections on COVID-19 and anti-hypertensives drugs", Drug Discov Ther, 14, pp.105~106 (2020)
  122. Mackey K, "Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults : a living systematic review", Ann Intern Med, 173, pp.195~203 (2020)
  123. Mehta N, "Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019(COVID-19)", JAMA Cardiol, 5, pp.1020~1026 (2020)
  124. Jung SY, "Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea : a nationwide population-based cohort study", Clin Infect Dis, 71, pp.2121~2128 (2020)
  125. Raisi-Estabragh Z, "Renin-angiotensin-aldosterone system blockers are not associated with coronavirus disease 2019(COVID-19)hospitalization : study of 1, 439 UK Biobank cases", Front Cardiovasc Med, 7, pp.138~ (2020)
  126. De Spiegeleer A, "The effects of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents", J Am Med Dir Assoc, 21, pp.909~914 (2020)
  127. Zhang XJ, "In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19", Cell Metab, 32, pp.176~187 (2020)
  128. Bean DM, "Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust", Eur J Heart Fail, 22, pp.967~974 (2020)
  129. Fosbol EL, "Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality", JAMA, 324, pp.168~177 (2020)
  130. Vaduganathan M, "Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19", N Engl J Med, 382, pp.1653~1659 (2020)
  131. Bavishi C, "Coronavirus disease 2019(COVID-19)infection and renin angiotensin system blockers", JAMA Cardiol, 5, pp.745~747 (2020)
  132. South AM, "Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic", Nat Rev Nephrol, 16, pp.305~307 (2020)
  133. Zhang P, "Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19", Circ Res, 126, pp.1671~1681 (2020)
  134. Grover A, "A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers", Eur Heart J Cardiovasc Pharmacother (2020)[DOI]
  135. Lam KW, "Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome", J Infect Dis, 222, pp.1256~1264 (2020)
  136. Oussalah A, "Long-term ACE inhibitor", ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19 : results from a referral center cohort in the north east of France, 2020, pp.71, 2447~2456
  137. Liu Y, "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury", Sci China Life Sci, 63, pp.364~374 (2020)
  138. Lopes RD, "Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers : impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2). The BRACE CORONA Trial", Am Heart J, 226, pp.49~59 (2020)

관련 논문AI추천

The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigmsMcLachlan Craig Steven대한고혈압학회 · Clinical Hypertension2020 · 제26권 제4호코로나바이러스19 감염증과 안지오텐신전환효소2신진호대한내과학회 · 대한내과학회지2020 · 제95권 제4호Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?김광일, 김대희, 김주한, 김현창, 박성하, 성기철, 손일석, 신진호, 유승기, 이해영, 임상현, 정욱진, 조은주, 편욱범, Korean Society of Hypertension대한고혈압학회 · Clinical Hypertension2020 · 제26권 제3호Treatment of diabetic kidney disease: current and future targets김미경대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제4호New therapeutic agents in diabetic nephropathy김예니, 박철휘대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제1호Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertensionDong-Ju Choi, Il-Young Oh, Ji Hyun Lee, Jin Joo Park, Jinwoo Lee, Seong Jin Jo, Youngjin Cho, Young-Seok Cho대한내과학회 · The Korean Journal of Internal Medicine2021 · 제36권 제1호

이 간행물의 다른 논문 (28건)

Recent advances in the management of difficult bile-duct stones: a focus on single-operator cholangioscopy-guided lithotripsy동석호, 오치혁pp. 235-246Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitusSoo-Yeon Choi, Seung-Hyun Kopp. 263-270How lessons learned from the 2015 Middle East respiratory syndrome outbreak affected the response to coronavirus disease 2019 in the Republic of KoreaJi Yun Noh, Hee Jin Cheong, Woo Joo Kim, Tae Un Yang, Joon-Young Songpp. 271-285Direct-acting antivirals trigger a favorable, sustained virological response in patients with chronic hepatitis C infections and hepatocellular carcinomaWon Sohnpp. 286-287The balance between clinical convenience and the new concepts of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathiesHyun-Sook Kimpp. 288-288
원문 보기